New Aids Therapy for Children The Nation, Kenya April 28, 2005 Nelly Thece Nairobi For the first time, an easy-to-use fixed-dose triple combination treatment for children infected with HIV has been developed with plans already underway to have it registered in Kenya. Trading under the brand name Emtri, the triple combination oral suspension- lamivudine, stavudine and nevirapine - was launched in India recently by former Zambian President Dr Kenneth Kaunda. Speaking to Horizon in Nairobi last week, Mr A K Khanna, the Executive Director of Emcure Pharmaceuticals Limited of India who have developed the new preparation, said they propose to sell the product at no profit to Africa and other developing countries, 'as our contribution in the fight against the scourge.' "We have done estimates and are confident we can offer the drug at no profit. We are able to cover the estimated number of children infected with the virus, in any case some for practical reasons will not be using our preparation, " he said. There are about 100, 000 children infected with HIV Aids in Kenya according to recent World Health Organisation estimates. The small number of children infected and most of them in poor countries make them an unattractive client segment for most drug companies to invest in. Drug companies have little interest in developing or marketing paediatric formulations adapted to poor countries, such as fixed-dose combinations or breakable or chewable tablets. Medecins Sans Frontieres MSF ; has already demonstrated that treating children with HIV Aids is much more expensive and difficult than treating adults. Simplified ways to treat HIV Aids in adults have become available to patients in developing countries within the past two years. Most adult patients in developing countries now take either a triple fixed-dose combination treatment one pill twice a day or one double combination plus a third drug. But neither the triple nor double combinations are available in dosages for children. When childhood doses are available, they come at a premium and zidovudine. Zidovudine lamivudine is not a cure and dilantin phenytoin ; treats different types of seizures epilepsy. STAVUDINE d4T ; + LAMIVUDINE 3TC ; Formulations Oral solution: stavudine 10 mg plus lamivudine 40 mg 5ml Tablets: d4T 40 mg ; plus 3TC 150 mg ; or d4T 30 mg ; plus 3TC 150 mg ; Dosing Target dose: stavudine: 1 mg kg dose twice daily; lamivudine: 4 mg kg dose twice daily Maximum dose: One 40 mg d4T-based tablet twice daily General comments See comments under individual drug components. Tablets: Preferably, should not be split unless scored. STAVUDINE d4T ; + LAMIVUDINE 3TC ; + NEVIRAPINE NVP ; Formulations Tablet: d4T 40 mg ; plus 3TC 150 mg ; plus NVP 200 mg ; or d4T 30 mg ; plus 3TC 150 mg ; plus NVP 200 mg ; As of June 2006 not yet WHO prequalified: Tablet: 6 mg stavudine 30 mg lamivudine 50 mg nevirapine baby ; Tablet: 12 mg stavudine 60 mg lamivudine 100 mg nevirapine junior ; Suspension: stavudine 10 mg 5 ml plus lamivudine 40 mg plus neviraprine 70 mg Dosing Target dose: stavudine: 1 mg kg dose twice daily; lamivudine: 4 mg kg dose twice daily; nevirapine: 160-200 mg m2 dose twice daily Maximum dose: One 40 mg d4T-based tablet twice daily General comments Contains a fixed dose of NVP, therefore cannot be used for nevirapine induction as nevirapine dose escalation required see NVP dosing recommendations ; . See comments under individual drug components. Tablets: Preferably, should not be split unless scored. ZIDOVUDINE ZDV ; + LAMIVUDINE 3TC ; Combivir ; Formulation Tablet: ZDV 300 mg ; plus 3TC 150 mg ; Dosing Target dose: Zidovudine: 180 - 240 mg m2 dose twice daily Lamivudine: 4 mg kg dose twice daily Maximum dose: 1 tablet dose twice daily General comments See comments under individual drug components. Tablets: No food restrictions. Can be crushed and contents mixed with a small amount of water or food and immediately taken. Store between 2C and 30C. ZIDOVUDINE ZDV ; + LAMIVUDINE 3TC ; + ABACAVIR ABC ; Trizivir ; Formulation Tablet: ZDV 300 mg ; plus 3TC 150 mg ; plus ABC 300 mg ; Dosing Target dose: Zidovudine: 180-240 mg m2 dose twice daily; Lamivudine: 4 mg kg dose twice daily; Abacavir: 8 mg kg dose twice daily Maximum dose: 1 tablet dose twice daily General comments See comments under individual drug components. Parents must be warned about potential hypersensitivity reaction. ABC should be stopped permanently if hypersensitivity reaction occurs. Tablets: Should not be split. TRIMETHOPRIM SULFAMETHOXAZOLE Cotrimoxazole, Septrim, Bactrim, TMP SMZ ; Dosing Recommendations for Cotrimoxazole Prophylaxis for Infants and Children Age Range 6 months 6 months-5 years 5-14 years 14 years Suspension 40 mg TMP 200 mg SMZ per 5ml 2.5 ml daily 5 ml daily 10 ml daily Single-strength tablet 80 mg TMP 400 mg SMZ 1 4 tablet daily 1 2 tablet daily 1 tablet daily 2 single-strength or 1 double-strength tablet daily and compazine.
TABLE 3. AGENTS PENDING FDA APPROVAL Generic Name Approvable Agents Abacavir, lamivudine, zidovudine Bivalirudin Trizivir GlaxoWellcome ; Angiomax The Medicines Company ; Yasmin 28 Berlex ; Foradil Novartis ; Treatment of HIV infection Anticoagulant for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty Oral contraceptive Treatment of asthma and bronchoconstriction in adults and children 5 years of age with reversible obstructive airway disease; prevention of exercise-induced bronchospasmi in adults and children 12 years of age Acute treatment of migraine headaches Elan ; Galantamine Latanoprost timolol Reminyl Johnson & Johnson ; Xalcom Pharmacia ; Treatment of mild-to-moderate Alzheimer's type dementia Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers, prostaglandins, or other IOP-lowering medications. Treatment of bipolar I disorder Intravenousproton pump inhibitor Treatment of irritable bowel syndrome 8 00 6 Brand Name Company ; Indication Date.
Comply with the monograph for "Tablets" * . Definition. Zidovudine and lamivudine tablets contain zidovudine and lamivudine. They contain not less than 90.0 % and not more than 110.0 % of the amounts of zidovudine C10H13N5O4 ; and lamivudine C8H11N3O3S ; stated on the label. Identity tests A. Carry out test A.1. or, where UV detection is not available, test A.2. A.1. Carry out the test as described under 1.14.1 Thin-layer chromatography * , using silica gel R6 as the coating substance and a mixture of 90 volumes of dichloromethane R, 10 volumes of methanol R and 3 volumes of glacial acetic acid R as the mobile phase. Apply separately to the plate 10 l of each of the following 2 solutions. For solution A ; , shake a quantity of the powdered tablets equivalent to about 50 mg of Lamivurine about 100 mg of Zidovudine ; with 50 ml of methanol R, filter, and use the filtrate. For solution B ; , use 2.0 mg of zidovudine RS and 1.0 mg of lamivudine RS per ml of methanol. After removing the plate from the chromatographic chamber, allow it to dry in a current of cool air, and examine the chromatogram in ultraviolet light 254 nm and prochlorperazine. Loyd V. Allen, Jr., Ph.D., FACA, FAPhA INTRODUCTION AND DEFINITIONS Drugs can be introduced into the lungs easily by the patient inhaling a "dose" of a drug in a properly designed dosage form that is caught up in the flow of air and carried into the deep recesses of the pulmonary environment. Drugs generally can be transported by the air stream into the respiratory bronchiole and the alveolar region when in the form of a vapor, very fine powder or as a solution in the form of an "aerosol". An aerosol is generally a dispersed system consisting of a solid or liquid internal phase in an outer gaseous phase. An example of a natural aerosol is a mist water air ; and dust solid air ; . Products administered by inhalation can produce either a local or a systemic effect. Drugs commonly administered for respiratory purposes include bronchodilators corticosteroids, antitussives, expectorants, surfactants, respiratory stimulants and therapeutic gases. Aromatherapy is a contemporary term used to describe one of the age-old methods of drug administration. Today, however, the term aromatherapy is used primarily to refer to the use of volatile aromatic oils that are used as room sprays, massage products, room fresheners and even as inhalants when placed in hot water. There are numerous advantages of oral inhalation products, including a rapid onset of action, bypassing the first-pass effect, avoiding drug degradation in the gastrointestinal tract, low dosages to minimize adverse reactions, dose titration capability, good for prn dosing, alternate route when other drugs may chemically or physically interact with concurrent drugs, and an alternate route for drugs with erratic oral or parenteral administration pharmacokinetics. The ultimate deposition of inhalation aerosols is dependent upon 1 ; the products formulation, 2 ; the design of components packaging container, 3 ; administration skills and techniques of the product user, and.

Following administration of radiolabeled emtricitabine, approximately 86% is recovered in the urine and 13% is recovered as metabolites. These metabolites include 3-sulfoxide diastereomers and their glucuronic acid conjugate.7 with a creatinine clearance below 30 ml minute or in patients with end-stage renal disease who need dialysis.5 comparing emtricitabine 200 mg once daily with the NRTI lamivudine 3TC, Epivir, GlaxoSmithKline ; 150 mg twice daily, in combination with the NRTI stavudine d4T, Zerit, Bristol-Myers Squibb Immunology ; 40 mg twice daily or the NRTI zidovudine ZDV, AZT, Retrovir, GlaxoSmithKline ; 300 mg twice daily plus a PI or NNRTI in 440 patients. The patients were following a lamivudine-containing triple-antiretroviral regimen for at least 12 weeks before entry into the study, and their HIV RNA levels were below 400 copies ml. The patients were randomly selected, in a 1: 2 ratio, to either continue therapy with lamivudine or to switch to emtricitabine.5, 9 At the time of enrollment into the study, the median duration of prior antiretroviral and lamivudine therapies had been 27.6 and 18 months, respectively. The median HIV RNA level was 1.7 log10 copies ml, and the mean CD4 cell count was 527 cells mm3. There were no statistically significant differences between the treatment arms and coreg. Similarly, there was no significant difference between the group that received the four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz and the groups that received the three-drug regimens beginning with zidovudine, lamivudine, and nelfinavir hr, 06 ; or zidovudine, lamivudine, and efavirenz hr, 45.
As a student and a person with parkinson's, i ask, in this day of medicine, why are there no blood tests to determine parkinson's and losartan. Geoff Isbister is an early career researcher with a major interest in clinical toxicology. He is a lecturer in clinical pharmacology at the University of Newcastle, as well as a clinical toxicologist and emergency physician at the Newcastle Mater Misericordiae Hospital and honorary consultant to the NSW Poison Information Centre. He has a particular interest in continuous data collection in overdose patients and correlation with drug concentrations. He also has extensive experience in clinical toxicology, with current collaborative research in arthropod, snake and marine envenomations with poison centres and museums around Australia, for instance, lamivudine price.
References: 1. Hosseinipour MC, Corbett AH, Kanyama C et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS: Volume 21 1 ; 2 January 2007 p 59-64. 2. Lowering dose of d4T can maintain efficacy and reduce side effects. HIV Treatment Bulletin Volume 5 Number 7 Aug Sep 2004 : i-base pub htb v5 htb5-7 Lowering 07 3. Lower doses of d4T produce similar efficacy and reduced side effects. HIV Treatment Bulletin Volume 4 Number 10 December 2003 : i-base pub htb v4 htb4-10 Lower 02 and crestor. Entecavir shows some efficacy against lamivudine resistance hbv, but this is partial, and higher doses are required!

See also list of notable people with cystic fibrosis references andersen dh.
The children ingested 3 mg budesonide as a single oral dose on day 1, thrice daily from days 2 to 7, and once in the morning of day 8. On day 1 and on day 8, single-dose and steady-state pharmacokinetic and and duloxetine.

Aiming in part to demonstrate the affordability of providing ARV treatment in a resource-limited setting, the Khayeltisha ARV treatment programme is implementing strategies to minimize costs. The importation of generic drugs from overseas manufacturers dramatically reduced the costs of treatment. As few generic ARV drugs are registered in South Africa, MSF obtained permission from the South African Medicines Control Council under the Medicines Act Section 21 ; for the use of unregistered generic ARV drugs. Authorization required sufficient evidence about drug quality. Following a collaboration agreement between MSF and the Brazilian government, MSF started to source generic versions of ARV drugs for its Khayelitsha project from the Brazilian state manufacturer, FarManguinhos, in January 2002. The price of the first-line regimen zidovudine lammivudine and nevirapine ; was then US$ 1.55 per person per day. This price was half the cost of the lowest possible price offered by the proprietary companies to governments US$ 3.00 per person per day ; and nearly a quarter of the price in the private sector US$ 5.50 per person per day ; . Later in 2002, the price of this Brazilian combination dropped further to US$ 1.08 per person per day. MSF recently received authorization from the South African Medicines Control Council to source drugs from different manufacturers worldwide, opening the chances to get the lowest prices. Simultaneously, we have worked with the National Health Laboratory Services to reduce the price of laboratory tests, especially viral load and CD4 count. The development of the pan-leucogating protocol AffordCD4TM ; and its immediate implementation at the National Health Laboratory Services allowed a price reduction from US$ 24 per test to US$ 8.30 per test. Negotiations between the National Health Laboratory Services and the proprietary companies that produce viral load kits led to a slight decrease of the cost of viral load testing in the public sector US$ 45 per test ; . MSF believes that the price of viral load testing can still be cut dramatically when companies apply the offers to which they have committed. The target cost for the package of two viral loads and two CD4 counts in the public sector is US$ 70 per year. By using generic ARV drugs and reducing the price of laboratory tests, MSF has cut the annual real cost per person of ARV treatment from US$ 1366 in January 2002 to US$ 536 in April 2003 adjusted to fluctuations of exchange rate ; . This price is based on the regimen zidovudine lammivudine and nevirapine, and two viral load tests and two CD4 tests per year.

You see your future. You see ultraproductive engineering and seamless information everywhere for true operational excellence. You'll get there with PROFINET. Based on Industrial Ethernet, PROFINET is open and the most comprehensive networking solution for all applications. PROFINET is the most advanced real-time architecture including high-performance motion control. PROFINET utilizes well-established IT standards and fully supports TCP IP. PROFINET is integrated, company-wide communication from management information systems down to the field level and with full real-time capability. w w w. ANTIRETROVIRALS NRTIs- abacavir Ziagen ; , abacavir lamivudine Epzicom ; , abacavir lamivudine zidovudine Trizivir ; , didanosine ddI, Videx, Videx EC ; , emtricitabine Emtriva ; , lamivudine Epivir, 3TC ; , lamivudine zidovudine Combivir ; , stavudine d4T, Zerit ; , tenofovir Viread ; , tenofovir emtricitabine Truvada ; , zidovudine AZT, Retrovir ; . PIs- amprenavir Agenerase ; , atazanavir Reyataz ; , fosamprenavir Lexiva ; , indinavir Crixivan ; , lopinavir ritonavir Kaletra ; , nelfinavir Viracept ; , ritonavir Norvir ; , saquinavir Fortovase, Invirase ; . NNRTIsdelavirdine Rescriptor ; , efavirenz Sustiva ; , nevirapine Viramune ; . Other- hydroxyurea Hydrea ; . Entry Inhibitors- enfuvirtide Fuzeon ; . OI DRUGS PHS "A1 OI"s- acyclovir Zovirax - generic only ; , azithromycin Zithromax ; , clarithromycin Biaxin ; , famciclovir Famvir ; , fluconazole Diflucan ; , itraconazole Sporonox ; , leucovorin Folinic Acid ; , pyrimethamine Daraprim ; , sulfadiazine, TMP SMX generics Bactrim, Septra ; . Other OIs- atovaquone Mepron ; , clindamycin Cleocin ; , clotrimazole Mycelex ; , dapsone, ethambutol Myambutol ; , ketoconazole Nizoral ; , primaquine, rifabutin Mycobutin ; , valacyclovir Valtrex ; , valganciclovir Valcyte ; . Hepatitis C- none. ALL OTHERS amitriptyline Elavil ; , bupropion Wellbutrin ; , citalopram Celexa ; , fluoxetine Prozac ; , nefazodone Serzone ; , paroxetine Paxil ; , sertaline Zoloft ; , trazodone Desyrl ; , venlafaxine Effexor ; . Removed in 2004 - zalcitabine ddC, Hivid.

Triglycerides amongst the ABT-378 r arm 9% versus 1% ; . More people left the nelfinavir arm than the ABT-378 r arm, however; 24% versus 17% overall, including 4% versus 2% for study drug related side-effects, and 9% versus 1% for virological failure nelfinavir versus ABT-378 r respectively.

Bernstein, P.A. 1996 ; Middleware: a model for distributed system services. Communications of the ACM. Vol. 39, Num. 2. ACM Press 1996 ; 86-98. EPCglobal 2005 ; Electronic Product Code. Retrieved February 26, 2005, from : epcglobalinc . Ishii, H. & Ullmer, B. 1997 ; Tangible Bits: Towards Seamless Interfaces between People, Bits and Atoms, in Proceedings of Conference on Human Factors in Computing Systems CHI '97 ; , ACM Press, 234-241. Kindberg, T., Barton, J., Morgan, J., Becker, G., Caswell, D., Debaty, P., Gopal, G., Frid, M., Krishnan, V., Morris, H., Schettino, J., Serra, B. & Spasojevic, M. 2000 ; People, places, things: Web presence for the real world. Mobile Computing Systems and Applications, 2000 Third IEEE Workshop on. 7-8 Dec. 2000. 19-28. Konkel, M., Leung, V., Ullmer, B. & Hu, C. 2004 ; Tagaboo: a collaborative children's game based upon wearable RFID technology. Personal Ubiquitous Computing, Springer Verlag, Volume 8, Number 5. 382-384. OASIS 2004 ; Introduction to UDDI: Important Features and Functional Concepts. Retrieved February 24th, 2005, from : uddi pubs uddi-tech-wp . Object Management Group 2005 ; CORBA. Retrieved 24th, 2005, from : corba . Rekimoto, J., Ayatsuka, Y. & Kohno, M. 2003 ; SyncTap: An Interaction Technique for Mobile Networking, MOBILE HCI 2003. Smyth, M., Raijmakers, B. & Munro, J. 2004 ; Who I and where I Switching and Stitching in the digital age. International Design Conference Design 2004 ; , Dubrovnik, May 2004. Sun Microsystems 2004 ; Java Remote Method Invocation. Retrieved February 24th, 2005, from : java.sun products jdk rmi . Sun Microsystems 2005 ; Jini Network Tehcnology. Retrieved 24th, 2005, from : sun software jini. Swindells, C., Inkpen, K.M., Dill, J.C., Tory, M. 2002 ; That one there! pointing to establish device identity. In: Symposium on User Interface Software and Technology UIST'02 ; 151-160. UserLand Software 2003 ; XML-RPC. Retrieved February 26, 2005 from : xmlrpc . Want, R., Fishkin, K.P., Gujar, A., Harrison, B.L. 1999 ; Bridging physical and virtual worlds with electronic tags. Conference on Human Factors in Computing Systems. 370-377. W3C 2003 ; SOAP Version 1.2 Part 0: Primer, W3C Recommendation 24 June 2003. Retrieved February 24th, 2005, from : w3 TR 2003 REC-soap12-part0-20030624. Is antiarrhythmic drug therapy needed?. Your browser does not support script home sitemap contact treatment guidelines v adults & adolescents october 10, 2006 ; v pediatrics october 26, 2006 ; v perinatal guidelines october 12, 2006 ; v tb hiv a clinical manual prescribing information for the use of a registered medical practitioner or hospital or laboratory only lamivudine with zidovudine tablets ip & efavirenz tablets ip composition: each kit contains, two tablets in part a and one tablet in part b, with composition as follows: part a: lamivudine with zidovudine tablets ip each film-coated tablet contains: lamivudine ip - 150 mg zidovudine ip - 300 mg each film-coated tablet contains: efavirenz ip - 600 mg colour: iron oxide yellow & titanium dioxide ip description: this combination kit contains the nucleoside reverse transcriptase inhibitors lamivudine & zidovudine and the non-nucleoside reverse transcriptase inhibitor efavirenz. GlaxoSmithKline has received traditional approval status for Trizivir for the treatment of human immunodeficiency virus HIV ; infection. This combination tablet contains three nucleoside reverse transcriptase inhibitors: Epivir lamivudine, 3TC ; , Retrovir zidovudine, ZDV ; , and Ziagen abacavir sulfate, ABC ; . The FDA grants traditional approval for a drug based on data from trials of 48 weeks or more; the agency granted accelerated approval for Trizivir in 2000, based on an analysis of 24-week data. This agent is taken as a single tablet, twice a day, with no food or water restrictions. It can be used in combination with other antiretroviral agents or alone. The company also markets two other fixed-dose-combination tablets: Combivir Epivir Retrovir ; and EpzicomTM Epivir Ziagen ; . Source: GlaxoSmithKline, May 16, 2005.

ANTIRETROVIRALS NRTIs- abacavir Ziagen ; , abacavir lamivudine Epzicom ; , abacavir lamivudine zidovudine Trizivir ; , didanosine ddI, Videx, Videx EC ; , emtricitabine Emtriva ; , lamivudine Epivir, 3TC ; , lamivudine zidovudine Combivir ; , stavudine d4T, Zerit ; , tenofovir Viread ; , tenofovir emtricitabine Truvada ; , zalcitabine ddC, Hivid ; , zidovudine AZT, Retrovir ; . PIs- amprenavir Agenerase ; , atazanavir Reyataz ; , fosamprenavir Lexiva ; , indinavir Crixivan ; , lopinavir ritonavir Kaletra ; , nelfinavir Viracept ; , ritonavir Norvir ; , saquinavir Fortovase, Invirase ; . NNRTIs- delavirdine Rescriptor ; , efavirenz Sustiva ; , nevirapine Viramune ; . Entry Inhibitorsenfuvirtide Fuzeon ; . OI DRUGS PHS "A1 OI"s- acyclovir Zovirax ; , azithromycin Zithromax ; , clarithromycin Biaxin ; , fluconazole Diflucan ; , itraconazole Sporonox ; , leucovorin, TMP SMX Bactrim, Septra ; . Other OIs- atovaquone Mepron ; , clotrimazole Mycelex, Gyne-Lotrimum ; , dapsone, ethambutol Myambutol ; , flucytosine Ancobon ; , ketoconazole Nizoral ; , metronidazole Flagyl ; , nystatin Mycostatin ; , pentamidine NebuPent, Pentam ; , rifabutin Mycobutin ; , valganciclovir Valcyte ; . Hepatitis C- none. TREATMENTS FOR METABOLIC DISORDERS Hyperlipidemia- atorvastatin Lipitor ; , fenofibrate Tricor ; , gemfibrozil Lopid ; , pravastatin Pravachol ; . Wasting- Testosterone. ALL OTHERS acetominophen hydrocodone Vicodin ; , amantadine Symmetrel ; , amitriptyline Elavil ; , bupropion Wellbutrin ; , buspirone BuSpar ; , carbamazepine Tegretol ; , cetaminophen + codeine Tylenol #3, Tylenol + codeine ; , chlorhexidine gluconate Peridex ; , clonidine hydrochloride ApoClonidine, Catapress, Nu-Clonidine ; , carbamazepine Tegretol ; , citalopram Celexa ; , desipramine Norpramine, Pertofrane ; , diphenhydramine Benadryl ; , diphenoxylate atropine Lomotil ; , esomeprazole magnesium Nexium ; , famotidine Pepcid ; , fluoxetine Prozac ; , gabapentin Neurontin ; , hydroxyzine Vistaril, Atarax ; , klonopin Clonazepam ; , lithium carbonate, loperamide hydrochloride Imodium ; , metoprolol Lopressor, Toprol XL ; , morphine sulfate Oramorph analgesic patches ; , nefazodone Serzone ; , niacin vitamin B3 Niaspan ; , omeprazole Prilosec ; , pantoprazole Protonix ; , paroxetine Paxil ; , premarin, phenobarbital Solfoton ; , phenytoin Dilantin ; , prochlorperazine Compazine ; , promethazine Phenergan ; , propoxyphene N APAP Darvocet ; , provera, rabeprazole sodium Aciphex ; , sertraline Zoloft ; , sodium valproate Depakote ; , temazepam Restoril ; , tramadol hydrochloride Ultrarn ; , trazodone Desyreo ; , tricyclic antidepressants Sinequan, Tofranil ; , venlafaxine Effexor ; , zolpidem tartrate Ambien ; . Removed in 2004 - famciclovir Famvir ; , ganciclovir Cytovene ; , propanolol Inderal ; , simvastin Zocor.